{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","groups":[{"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","id":"OG000","title":"IPH2101 0.0003 mg/kg"},{"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","id":"OG001","title":"IPH2101 0.003 mg/kg"},{"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","id":"OG002","title":"IPH2101 0.015 mg/kg"},{"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","id":"OG003","title":"IPH2101 0.075 mg/kg"},{"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","id":"OG004","title":"IPH2101 0.3 mg/kg"},{"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","id":"OG005","title":"IPH2101 1 mg/kg"},{"description":"Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease","id":"OG006","title":"IPH2101 3 mg/kg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From start of the treatment to end of study or disease progression","title":"Number of Evaluable Patients With Stable Disease. \"Evaluable\" is Defined as 2 Consecutive M Protein Assessments","type":"SECONDARY","unitOfMeasure":"Number of participants"}